The Statin Market Gets Two New Players
Executive Summary
The market for statins, cholesterol-lowering drugs, just got more crowded as Bayer announced a co-promotion with SmithKline, which in turn followed the blockbuster deal for {lipitor} between Pfizer and Warner-Lambert. But some analysts already see a segmentation coming, with Bayer/SB going head-to-head against Bristol-Myer Squibb's {Pravachol}, while {Lipitor} competes against Merck's {Zocor}.
You may also be interested in...
US FDA Requests Ranitidine Removal But Also Encourages Research For Stable Formulations
FDA requests immediate removal of ranitidine OTC and Rx drugs after third-party testing finds contaminant NDMA increases during storage, especially at higher temperatures. CDER Director Janet Woodcock asks firms to reformulate products to be stable as the ingredient remains approved.
Takeda Gets New India Chief, Mandate To Broaden Access
Takeda appoints new country head for India and aims to improve patient access to innovative medicines in the largely out-of-pocket market.
US FDA Exploring Virtual Advisory Cmtes.; Might Sponsors Want To Wait For In-Person Meetings?
Likelihood of webcast-only advisory committee meetings may depend on the extent of the coronavirus outbreak, Office of New Drugs Director Peter Stein tells the Pink Sheet in an interview.
Need a specific report? 1000+ reports available
Buy Reports